On June 11, 2018, Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, announced a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur, the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five uOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.